;
MRI DYE CONTAINING GADOLINIUM
Intro
Symptoms
FDA
COI
COI Continued
Research
Steps
Patient Perspective
Etc.
Blog
Paula M. Jacobs
National Cancer Institute
DID NOT DISCLOSE ON "RESEARCH ROADMAP" THAT SHE HAD CO-AUTHORED A PAPER WITH GUERBET ON IRON OXIDE CONTRAST
(
FERUMOXTRAN) DEVELOPERS: AMAG PHARMACEUTICALS INC. (USA) GUERBET, SA (EU
)
WAS A VOTING MEMBER AT 2017 FDA MEETING ON GADOLINIUM SAFETY
Matthew S. Davenport
University of Michigan
COMMITTEE ON DRUGS AND CONTRAST MEDIA FOR ACR (AMERICAN COLLEGE OF RADIOLOGY)
RECEIVES ROYALTIES FROM WOLTERS KLUWER
RSNA PRESENTER 2013, 2014, 2015,
2016 "CONTROVERSIES IN INTRAVENOUS CONTRAST MEDIA
..." (+ RADBRUCH & MCDONALD),
2017 "CONTROVERSIES IN INTRAVENOUS CONTRAST MEDIA..." (
+RADBRUCH & MCDONALD
)
,
2018 "USE OF IODINATED AND GADOLINIUM-BASED CONTRAST MEDIA"
(
+MCDONALD
)
SPR (SOCIETY OF PEDIACTRIC RADIOLOGY) 2018
"POST-CONTRAST ACUTE KIDNEY DISORDER"
MRI safety, MRI side effects, Gadolinium, Toxic, MRI Contrast, MRI Dye, Safety, GBCA, NSF, ACR, Fibromyalgia, Radiology, Linear, Macrocylic, CTE, Football CTE, Chronic Traumatic Encephalopathy, multiple sclerosis, brain injury